Login
$PVLA
$144.90 +$0.30 (0.21%) After hours

$PVLA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 Form 4: Martini Jeffrey S, Chief Scientific Officer

Received 6,250 shares by exercise or conversion ($51.5K) · Sold 6,250 shares ($1.04M) · Received 6,250 shares by exercise or conversion ($61.2K) · 1 more

10 Nov 2026 144
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027

28 Oct 2026 SCHEDULE 13G/A
28 Oct 2026 8-K: Other Events

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

23 Oct 2026 Form 4: Goin Kathleen, Chief Operating Officer

Received 4,313 shares by exercise or conversion ($35K) · Sold 4,313 shares ($537K)

21 Oct 2026 144
14 Oct 2026 Form 4: Jenkins George M, Director

Sold 13,152 shares ($1.76M) · Sold 7,174 shares ($935K) · Sold 7,174 shares ($886K)

13 Oct 2026 144
18 Sep 2026 Form 4: Goin Kathleen, Chief Operating Officer

Received 4,302 shares by exercise or conversion ($34.9K) · Sold 4,302 shares ($655K)

16 Sep 2026 144
15 Sep 2026 Form 4: Jenkins George M, Director

Sold 12,371 shares ($1.87M) · Sold 13,352 shares ($2.03M) · Sold 1,777 shares ($267K)

11 Sep 2026 144
04 Sep 2026 Form 4: Kiritsy Christopher P, Director

Received 313 shares by exercise or conversion ($39.8K) · Sold 313 shares ($49.1K)

02 Sep 2026 144
20 Aug 2026 Form 4: Goin Kathleen, Chief Operating Officer

Received 4,302 shares by exercise or conversion ($34.9K) · Sold 4,302 shares ($655K)

19 Aug 2026 144
14 Aug 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support